USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Endotronics Inc.
Address:
8500 Evergreen Blvd
Coon Rapids, MN 55433
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $148,364.00 3
SBIR Phase II $449,675.00 1

Award List:

AUTOMATED CULTURE OF LYMPHOKINE-ACTIVATED KILLER CELLS

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$48,965.00
Agency:
HHS
Principal Investigator:
Abstract:
Adoptive cellular immunotherapy has recently demonstrated enormous promise as a metastatic cancer treatment. despite this promise, lymphokine-activated killer (lak) cell therapy has been severely limited by the prohibitive task of in vitro immune cell proliferation. recently, hollow-fiber mammalian… More

HOLLOW-FIBER BIOREACTOR WITH IMPROVED OXYGENATION

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$49,845.00
Agency:
HHS
Principal Investigator:
Abstract:
Recombinant research has facilitated the in vitro productionof mammalian cell-secreted products. these products are used in the in vitro and in vivo diagnostic and therapeutic setting. products that have been approved or are in the approval process have projected market needs on the order of100… More

COMPACT CELL CULTURE DEVICE FOR CELLULAR IMMUNOTHERAPY

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$49,554.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

COMPACT CELL CULTURE DEVICE FOR CELLULAR IMMUNOTHERAPY

Award Year / Program / Phase:
1991 / SBIR / Phase II
Award Amount:
$449,675.00
Agency:
HHS
Principal Investigator:
Abstract:
Adoptive cellular immunotherapy (ci), specifically lymphokine-activated killer (lak) cells, has developed into a promising method for effective cancer therapy. unfortunately, lak cell therapy is limited by the labor-intensive task of generating large numbers of activated lymphocytes. conventional… More